BioSpace News Archive

NS Pharma, Inc. (NS Pharma; President, Tsugio Tanaka), a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; President, Toru Nakai), announced the publication of long-term efficacy and safety data based on analyses at 109 weeks from the 192-week open-label extension trial of a Phase 2 study of VILTEPSO® (viltolarsen) injection in the Journal of Neuromuscular Diseases.

Edgewise Therapeutics, Inc. announced that members of its senior management team will participate in the following upcoming investor conferences.

At a time when hospitals are under unprecedented logistical and financial strain, a new industry-wide report illuminates the potential for saving money and reducing waste and emissions by extending the life of “single-use” medical devices through reprocessing.

Takeda Pharmaceutical Company Limited announced that it will present data at two upcoming scientific congresses this spring: the 58th Annual Meeting of the American Society of Clinical Oncology, June 3-7 in Chicago, Ill. and the 30th Congress of the European Hematology Association, June 9-12 in Vienna, Austria.

Altoida, Inc., a precision neurology company pioneering non-invasive brain health measurement and neurological disease diagnostics with AI and augmented reality (AR), today announced the appointment of Dr. Antonella Santuccione Chadha as Chief Medical Officer.

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s investigational new drug (IND) application for its lead product candidate, JANX007.

Endeavor BioMedicines, a company that aims to improve cancer outcomes and accelerate cancer research using artificial intelligence, today announced a partnership that gives patients enrolling in Endeavor’s clinical trials access to the xCures platform to find the best available treatment options suited to their individual tumor profile.

Eureka Therapeutics and City of Hope Treat First Patient with GPC3 Targeting ARTEMIS ® T Cells (ECT204) for Advanced Liver Cancer.

Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that a submitted abstract was accepted for poster presentation at the 104th Annual Meeting of the Endocrine Society (ENDO 2022) taking place June 11-14, 2022, in Atlanta, GA.

Cybin Inc. ( NEO:CYBN ) (NYSE American:CYBN) ( Cybin or the Company ), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics TM ”, is pleased to announce the submission of an Investigational New Drug (“IND”) application to the U.S. Food and Drug Administration for its Phase 1/2a first-in-human clinical trial evaluating CYB003, a proprietary deuterated psilocybin analog, for the treatment of major depressive disorder (“MDD”).